The Effects of DPP-IV Inhibition in NOD Mice with Overt Diabetes Cited by

Fol. Biol. 2013, 59, 116-122

https://doi.org/10.14712/fb2013059030116

The Effects of DPP-IV Inhibition in NOD Mice with Overt Diabetes

Lenka Vargová¹, K. Zacharovová¹, E. Dovolilová¹, L. Vojtová¹, Z. Cimburek², F. Saudek¹

¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic
²Institute of Molecular Genetics of the ASCR, v. v. i., Prague, Czech Republic

Received December 2012
Accepted January 2013

Crossref Cited-by Linking

Currie Crawford, Bjerknes Christian, Framroze Bomi: Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors and Pancreatic Islet Cell Protection by Salmon-Derived Bioactive Peptides. Marine Drugs 2024, 22, 490. <https://doi.org/10.3390/md22110490>
Drakul Marija, \u010coli\u0107 Miodrag: Immunomodulatory activity of dipeptidyl peptidase\u20104 inhibitors in immune\u2010related diseases. Eur J Immunol 2023, 53. <https://doi.org/10.1002/eji.202250302>
Ding Lei, Gysemans Conny A., Stangé Geert, Heremans Yves, Yuchi Yixing, Takiishi Tatiana, Korf Hannelie, Chintinne Marie, Carr Richard D., Heimberg Harry, Pipeleers Daniel, Mathieu Chantal, Cignarella Andrea: Combining MK626, a Novel DPP-4 Inhibitor, and Low-Dose Monoclonal CD3 Antibody for Stable Remission of New-Onset Diabetes in Mice. PLoS ONE 2014, 9, e107935. <https://doi.org/10.1371/journal.pone.0107935>